Clinical Trial: Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis, Multicenter, Phase 4 Study

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07025460) titled 'Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis, Multicenter, Phase 4 Study' on June 09.

Brief Summary: This open-label, multicenter, single-arm phase 4 clinical study aims to evaluate the efficacy and safety of once-monthly subcutaneous administration of darbepoetin alfa (DARB) in maintaining hemoglobin (Hb) concentration in patients with anemia due to advanced chronic kidney disease (CKD) not receiving dialysis.

Anemia in CKD is a major contributor to cardiovascular morbidity and mortality. Alth...